The conventional classification of acute myocardial infarction (AMI) into ST-segment elevation (STEMI) and non-ST-segment elevation (NSTEMI) has long guided clinical decision-making. However, emerging ...

Heart attack death rates rose by 1.2% among adults younger than age 55 who were hospitalized between 2011 and 2022 with a first severe heart attack, according to a February study published in the ...

Acute coronary syndrome (ACS) encompasses a spectrum of clinical conditions precipitated by sudden, reduced blood flow to the myocardium. Often resulting from coronary plaque rupture and subsequent ...

SAN FRANCISCO, California — A small, phase 2 study, with a biomarker test for its primary end point, offers some encouraging hints that the P-selectin antagonist inclacumab may be able to reduce ...

Among patients presenting to the hospital with NSTEMI, an early invasive strategy based on symptom-to-catheter time is associated with a lower risk of all-cause mortality at 3 years, according to new ...

Medical Management/Treatment Initial treatment for suspected STEMI and NSTEMI requires a loading dose of nonenteric coated ASA at 162 to 325 mg (unless contraindicated), nitroglycerin in response to ...

The diagnostics advisory committee considered evidence on high-sensitivity troponin tests for the early rule out of non-ST-segment elevation myocardial infarction (NSTEMI) from several sources. Full ...

The effects of regionalized STEMI treatment protocols do not seem to have positively or negatively affected patients diagnosed with NSTEMI, according to new California registry data. The widespread ...